1.28
-0.02(-1.54%)
Currency In USD
Previous Close | 1.3 |
Open | 1.3 |
Day High | 1.3 |
Day Low | 1.27 |
52-Week High | 12.7 |
52-Week Low | 1.24 |
Volume | 80,345 |
Average Volume | 636,383 |
Market Cap | 4.13M |
PE | 18.29 |
EPS | 0.07 |
Moving Average 50 Days | 1.85 |
Moving Average 200 Days | 3.23 |
Change | -0.02 |
If you invested $1000 in 60 Degrees Pharmaceuticals, Inc. (SXTP) since IPO date, it would be worth $4.56 as of August 20, 2025 at a share price of $1.28. Whereas If you bought $1000 worth of 60 Degrees Pharmaceuticals, Inc. (SXTP) shares 1 year ago, it would be worth $164.1 as of August 20, 2025 at a share price of $1.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
GlobeNewswire Inc.
Yesterday at 12:54 PM GMT
90-day trial measuring change in general fatigue in chronic babesiosis patientsEnrollment expected to commence Q4 2025 and to be completed by Q2 2026Site has clinical expertise in infectious disease trials and access to a robust patient population wi
60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
GlobeNewswire Inc.
Aug 13, 2025 8:14 PM GMT
A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model$1.97 million cash on hand, runway through March 31, 2026 WASHINGTON, Aug. 13, 2025 (GLOBE NEWSWI
60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria
GlobeNewswire Inc.
Jul 17, 2025 12:01 PM GMT
Study will evaluate activity of tafenoquine against vector-borne pathogens, Borrelia (Lyme disease) and Bartonella in cell cultureBorrelia and Bartonella, together with Babesia, represent the "3Bs," pathogens most often present in individuals with ti